Effective antibacterials: At what cost? The economics of antibacterial resistance and its control

Anthony R. White; Martin Blaser; Otto Carrs; Gail Cassell; Neil Fishman; Robert Guidos; Stuart Levy; John Powers; Ragnar Norrby; Glenn Tillotson; Rick Davies; Steven Projan; Mike Dawson; Dominique Monnet; Marcus Keogh-brown; Kieran Hand; Sarah Garner; David Findlay; Chantal Morel; Richard Wise; Richard Bax; Frances Burke; Ian Chopra; Lloyd Czaplewski; Roger Finch; David Livermore; Laura J.V. Piddock; Tony White

doi:10.1093/jac/dkr260

Effective antibacterials: At what cost? The economics of antibacterial resistance and its control

Anthony R. White^*, Martin Blaser, Otto Carrs, Gail Cassell, Neil Fishman, Robert Guidos, Stuart Levy, John Powers, Ragnar Norrby, Glenn Tillotson, Rick Davies, Steven Projan, Mike Dawson, Dominique Monnet, Marcus Keogh-brown, Kieran Hand, Sarah Garner, David Findlay, Chantal Morel, Richard WiseRichard Bax, Frances Burke, Ian Chopra, Lloyd Czaplewski, Roger Finch, David Livermore, Laura J.V. Piddock, Tony White

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

62 Citations (Scopus)

Abstract

The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing development costs and regulatory hurdles, resulting in a decreasing chance of success and financial return. The supply of new effective agents is diminishing along with the number of companies engaged in antibacterial research and development. The BSAC Working Party on The Urgent Need:Regenerating Antibacterial Drug Discovery and Development identified the need to establish, communicate and apply the true health and economic value of antibacterials, along with the adoption of meaningful incentives, as part of the future model for antibacterial development. Robust data are needed on the cost of resistance and ineffective treatment of bacterial infection, along with national and local holistic analyses of the cost-benefit of antibacterials. An understanding of the true health and economic value of antibacterials and the cost of resistance across healthcare systems needs to be generated, communicated and used in order to set a pricing and reimbursement structure that is commensurate with value. The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed. A research and development model that succeeds in developing and delivering new antibacterial agents that address the health needs of society from start to finish, 'from cradle to grave', must be established.

Original language	English
Article number	dkr260
Pages (from-to)	1948-1953
Number of pages	6
Journal	Journal of Antimicrobial Chemotherapy
Volume	66
Issue number	9
DOIs	https://doi.org/10.1093/jac/dkr260
Publication status	Published - Sept 2011

Bibliographical note

Funding Information:
A. R. W. is an independent consultant, a retired employee and shareholder of GlaxoSmithKline, and in the past 5 years has received financial remuneration for consultancy or presentations from GSK and Chiron/ Novartis. D. L. has received conference, speaking and research support from numerous pharmaceutical companies. He holds shares in AstraZe-neca, Merck, Pfizer, Dechra, and GlaxoSmithKline, and, as executor, manages further holdings in GlaxoSmithKline and Eco Animal Health. He is an employee of the UK HPA and is a UK taxpayer. R. B. is currently a senior partner at Transcrip Partners LLP and works with several large and small pharmaceutical companies in the area of antibiotic development. He is also a non-executive director of Helperby Therapeutics Ltd. R. F. has provided consultative advice Destiny Pharma, GlaxoSmith-Kline, Menarini Recherche and Novartis. F. B. is an employee of Eli Lilly and Company Ltd. I. C. is a member of the Scientific Advisory Board of Destiny Pharma Ltd, and has recently received research funding from Cubist, Destiny, Galapagos, Leo, Pfizer, Novartis and Novacta. The remaining Members of the Working Party have none to declare.

Keywords

Drug development
Estimated net present values
Return on investment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkr260

Cite this

White, A. R., Blaser, M., Carrs, O., Cassell, G., Fishman, N., Guidos, R., Levy, S., Powers, J., Norrby, R., Tillotson, G., Davies, R., Projan, S., Dawson, M., Monnet, D., Keogh-brown, M., Hand, K., Garner, S., Findlay, D., Morel, C., ... White, T. (2011). Effective antibacterials: At what cost? The economics of antibacterial resistance and its control. Journal of Antimicrobial Chemotherapy, 66(9), 1948-1953. Article dkr260. https://doi.org/10.1093/jac/dkr260

@article{2019c78fa6ca4023b57176c358f59941,

title = "Effective antibacterials: At what cost? The economics of antibacterial resistance and its control",

abstract = "The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing development costs and regulatory hurdles, resulting in a decreasing chance of success and financial return. The supply of new effective agents is diminishing along with the number of companies engaged in antibacterial research and development. The BSAC Working Party on The Urgent Need:Regenerating Antibacterial Drug Discovery and Development identified the need to establish, communicate and apply the true health and economic value of antibacterials, along with the adoption of meaningful incentives, as part of the future model for antibacterial development. Robust data are needed on the cost of resistance and ineffective treatment of bacterial infection, along with national and local holistic analyses of the cost-benefit of antibacterials. An understanding of the true health and economic value of antibacterials and the cost of resistance across healthcare systems needs to be generated, communicated and used in order to set a pricing and reimbursement structure that is commensurate with value. The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed. A research and development model that succeeds in developing and delivering new antibacterial agents that address the health needs of society from start to finish, 'from cradle to grave', must be established.",

keywords = "Drug development, Estimated net present values, Return on investment",

author = "White, {Anthony R.} and Martin Blaser and Otto Carrs and Gail Cassell and Neil Fishman and Robert Guidos and Stuart Levy and John Powers and Ragnar Norrby and Glenn Tillotson and Rick Davies and Steven Projan and Mike Dawson and Dominique Monnet and Marcus Keogh-brown and Kieran Hand and Sarah Garner and David Findlay and Chantal Morel and Richard Wise and Richard Bax and Frances Burke and Ian Chopra and Lloyd Czaplewski and Roger Finch and David Livermore and Piddock, {Laura J.V.} and Tony White",

note = "Funding Information: A. R. W. is an independent consultant, a retired employee and shareholder of GlaxoSmithKline, and in the past 5 years has received financial remuneration for consultancy or presentations from GSK and Chiron/ Novartis. D. L. has received conference, speaking and research support from numerous pharmaceutical companies. He holds shares in AstraZe-neca, Merck, Pfizer, Dechra, and GlaxoSmithKline, and, as executor, manages further holdings in GlaxoSmithKline and Eco Animal Health. He is an employee of the UK HPA and is a UK taxpayer. R. B. is currently a senior partner at Transcrip Partners LLP and works with several large and small pharmaceutical companies in the area of antibiotic development. He is also a non-executive director of Helperby Therapeutics Ltd. R. F. has provided consultative advice Destiny Pharma, GlaxoSmith-Kline, Menarini Recherche and Novartis. F. B. is an employee of Eli Lilly and Company Ltd. I. C. is a member of the Scientific Advisory Board of Destiny Pharma Ltd, and has recently received research funding from Cubist, Destiny, Galapagos, Leo, Pfizer, Novartis and Novacta. The remaining Members of the Working Party have none to declare.",

year = "2011",

month = sep,

doi = "10.1093/jac/dkr260",

language = "English",

volume = "66",

pages = "1948--1953",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "9",

}

White, AR, Blaser, M, Carrs, O, Cassell, G, Fishman, N, Guidos, R, Levy, S, Powers, J, Norrby, R, Tillotson, G, Davies, R, Projan, S, Dawson, M, Monnet, D, Keogh-brown, M, Hand, K, Garner, S, Findlay, D, Morel, C, Wise, R, Bax, R, Burke, F, Chopra, I, Czaplewski, L, Finch, R, Livermore, D, Piddock, LJV & White, T 2011, 'Effective antibacterials: At what cost? The economics of antibacterial resistance and its control', Journal of Antimicrobial Chemotherapy, vol. 66, no. 9, dkr260, pp. 1948-1953. https://doi.org/10.1093/jac/dkr260

TY - JOUR

T1 - Effective antibacterials

T2 - At what cost? The economics of antibacterial resistance and its control

AU - White, Anthony R.

AU - Blaser, Martin

AU - Carrs, Otto

AU - Cassell, Gail

AU - Fishman, Neil

AU - Guidos, Robert

AU - Levy, Stuart

AU - Powers, John

AU - Norrby, Ragnar

AU - Tillotson, Glenn

AU - Davies, Rick

AU - Projan, Steven

AU - Dawson, Mike

AU - Monnet, Dominique

AU - Keogh-brown, Marcus

AU - Hand, Kieran

AU - Garner, Sarah

AU - Findlay, David

AU - Morel, Chantal

AU - Wise, Richard

AU - Bax, Richard

AU - Burke, Frances

AU - Chopra, Ian

AU - Czaplewski, Lloyd

AU - Finch, Roger

AU - Livermore, David

AU - Piddock, Laura J.V.

AU - White, Tony

N1 - Funding Information: A. R. W. is an independent consultant, a retired employee and shareholder of GlaxoSmithKline, and in the past 5 years has received financial remuneration for consultancy or presentations from GSK and Chiron/ Novartis. D. L. has received conference, speaking and research support from numerous pharmaceutical companies. He holds shares in AstraZe-neca, Merck, Pfizer, Dechra, and GlaxoSmithKline, and, as executor, manages further holdings in GlaxoSmithKline and Eco Animal Health. He is an employee of the UK HPA and is a UK taxpayer. R. B. is currently a senior partner at Transcrip Partners LLP and works with several large and small pharmaceutical companies in the area of antibiotic development. He is also a non-executive director of Helperby Therapeutics Ltd. R. F. has provided consultative advice Destiny Pharma, GlaxoSmith-Kline, Menarini Recherche and Novartis. F. B. is an employee of Eli Lilly and Company Ltd. I. C. is a member of the Scientific Advisory Board of Destiny Pharma Ltd, and has recently received research funding from Cubist, Destiny, Galapagos, Leo, Pfizer, Novartis and Novacta. The remaining Members of the Working Party have none to declare.

PY - 2011/9

Y1 - 2011/9

N2 - The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing development costs and regulatory hurdles, resulting in a decreasing chance of success and financial return. The supply of new effective agents is diminishing along with the number of companies engaged in antibacterial research and development. The BSAC Working Party on The Urgent Need:Regenerating Antibacterial Drug Discovery and Development identified the need to establish, communicate and apply the true health and economic value of antibacterials, along with the adoption of meaningful incentives, as part of the future model for antibacterial development. Robust data are needed on the cost of resistance and ineffective treatment of bacterial infection, along with national and local holistic analyses of the cost-benefit of antibacterials. An understanding of the true health and economic value of antibacterials and the cost of resistance across healthcare systems needs to be generated, communicated and used in order to set a pricing and reimbursement structure that is commensurate with value. The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed. A research and development model that succeeds in developing and delivering new antibacterial agents that address the health needs of society from start to finish, 'from cradle to grave', must be established.

AB - The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing development costs and regulatory hurdles, resulting in a decreasing chance of success and financial return. The supply of new effective agents is diminishing along with the number of companies engaged in antibacterial research and development. The BSAC Working Party on The Urgent Need:Regenerating Antibacterial Drug Discovery and Development identified the need to establish, communicate and apply the true health and economic value of antibacterials, along with the adoption of meaningful incentives, as part of the future model for antibacterial development. Robust data are needed on the cost of resistance and ineffective treatment of bacterial infection, along with national and local holistic analyses of the cost-benefit of antibacterials. An understanding of the true health and economic value of antibacterials and the cost of resistance across healthcare systems needs to be generated, communicated and used in order to set a pricing and reimbursement structure that is commensurate with value. The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed. A research and development model that succeeds in developing and delivering new antibacterial agents that address the health needs of society from start to finish, 'from cradle to grave', must be established.

KW - Drug development

KW - Estimated net present values

KW - Return on investment

UR - http://www.scopus.com/inward/record.url?scp=80051674450&partnerID=8YFLogxK

U2 - 10.1093/jac/dkr260

DO - 10.1093/jac/dkr260

M3 - Article

C2 - 21700625

AN - SCOPUS:80051674450

SN - 0305-7453

VL - 66

SP - 1948

EP - 1953

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 9

M1 - dkr260

ER -

Effective antibacterials: At what cost? The economics of antibacterial resistance and its control

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this